Base de dados : MEDLINE
Pesquisa : D02.455.326.271.665.202.495.325 [Categoria DeCS]
Referências encontradas : 3282 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 329 ir para página                         

  1 / 3282 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29429508
[Au] Autor:Ezzedine K
[Ad] Endereço:Service de dermatologie, hôpital Henri-Mondor et EpiDermE, EA 7379, université Paris-Est Créteil Val-de-Marne, 94010, Créteil, France. Electronic address: haled.ezzedine@aphp.fr.
[Ti] Título:[What's new in dermatological therapy?]
[Ti] Título:Quoi de neuf en thérapeutique dermatologique ?.
[So] Source:Ann Dermatol Venereol;143 Suppl 3:S37-S42, 2016 Dec.
[Is] ISSN:0151-9638
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Over the last year there has been major publications related to therapeutic trials in infectious dermatology, not only with regard to Herpes zoster subunit vaccine but also for the treatment of uncomplicated abscesses or scabies. In addition, biological treatments continue to be on the forefront, not only in the treatment of psoriasis but also in other chronic inflammatory dermatologic diseases such as atopic dermatitis and hidradenitis suppurativa, two diseases that significantly impact quality of life and for which there are to date, few therapeutic alternatives in moderate to severe forms. In addition, the treatment of cyclin-resistant papulopustular rosacea was also the subject of a large French controlled randomized controlled trial that could modify our therapeutic approach by the use of isotretinoin. Finally, the prevention of rashes induced by erlotinib with oral doxycyline is also part of this 2016 "what's new in dermatological therapeutics".
[Mh] Termos MeSH primário: Dermatopatias/tratamento farmacológico
[Mh] Termos MeSH secundário: Adalimumab/uso terapêutico
Antibacterianos/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Dermatologia
Cloridrato de Erlotinib/uso terapêutico
Vacina contra Herpes Zoster
Seres Humanos
Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico
Isotretinoína/uso terapêutico
Piperidinas/uso terapêutico
Inibidores de Proteínas Quinases/uso terapêutico
Pirimidinas/uso terapêutico
Pirróis/uso terapêutico
Dermatopatias/diagnóstico
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents); 0 (Antibodies, Monoclonal); 0 (Dermatologic Agents); 0 (Herpes Zoster Vaccine); 0 (Interleukin 1 Receptor Antagonist Protein); 0 (Piperidines); 0 (Protein Kinase Inhibitors); 0 (Pyrimidines); 0 (Pyrroles); 0 (SAR231893); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 87LA6FU830 (tofacitinib); DA87705X9K (Erlotinib Hydrochloride); EH28UP18IF (Isotretinoin); FYS6T7F842 (Adalimumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE


  2 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779325
[Au] Autor:Anderson M; Leman J
[Ad] Endereço:Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK.
[Ti] Título:Isotretinoin in acne: a single-centre experience.
[So] Source:Clin Exp Dermatol;41(8):934-936, 2016 Dec.
[Is] ISSN:1365-2230
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Fármacos Dermatológicos/uso terapêutico
Isotretinoína/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Esquema de Medicação
Feminino
Seres Humanos
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Dermatologic Agents); EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/ced.12920


  3 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28917459
[Au] Autor:Pedrosa AF; Duarte AF; Haneke E; Correia O
[Ad] Endereço:Centro de Dermatologia Epidermis, Instituto CUF, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Department of Dermatology and Venereology, Centro Hospitalar São João EPE, Porto, Portugal. Electronic address: anabastospedrosa@gmail.com.
[Ti] Título:Yellow facial papules associated with frontal fibrosing alopecia: A distinct histologic pattern and response to isotretinoin.
[So] Source:J Am Acad Dermatol;77(4):764-766, 2017 10.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Alopecia
Isotretinoína
[Mh] Termos MeSH secundário: Folículo Piloso
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170918
[St] Status:MEDLINE


  4 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28864554
[Au] Autor:DeKlotz CMC; Roby KD; Friedlander SF
[Ad] Endereço:MedStar Washington Hospital Center/Georgetown University Hospital, Washington, District of Columbia; and Cynthia.M.DeKlotz@medstar.net.
[Ti] Título:Dietary Supplements, Isotretinoin, and Liver Toxicity in Adolescents: A Retrospective Case Series.
[So] Source:Pediatrics;140(4), 2017 Oct.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Isotretinoin is the most effective acne therapy available, but has the potential for a number of adverse side effects, including transaminitis. The iPLEDGE isotretinoin program recommends avoiding some herbals and supplements due to potential side effects. However, little is known about the effects of protein supplements on the liver, particularly in patients taking isotretinoin. We designed a retrospective chart review to evaluate the symptoms, diagnosis, treatment, and outcome of patients on or preparing to take isotretinoin therapy who were concurrently ingesting protein or herbal supplementation and who developed transaminitis. In 100% (8/8) of cases, dietary supplementation was determined to be at least a possible cause of elevated liver transaminases. In 75% (6/8) of cases, dietary supplement appears to be the most likely cause at some point in their evaluation. Most of our patients' elevations in aspartate aminotransferase and/or alanine aminotransferase were likely caused by supplementation with protein, creatine, or herbal extracts, rather than prescribed isotretinoin or tetracycline antibiotics for acne. Hence, dietary supplementation may cause liver function abnormalities. As supplement usage appears common in teenagers, clinicians should consider counseling their patients to avoid these products, particularly when prescribing known hepatotoxic drugs.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Doença Hepática Induzida por Substâncias e Drogas/etiologia
Fármacos Dermatológicos/efeitos adversos
Suplementos Nutricionais/efeitos adversos
Isotretinoína/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Biomarcadores/metabolismo
Camellia sinensis/efeitos adversos
Doença Hepática Induzida por Substâncias e Drogas/diagnóstico
Doença Hepática Induzida por Substâncias e Drogas/enzimologia
Creatina/efeitos adversos
Fármacos Dermatológicos/uso terapêutico
Proteínas na Dieta/efeitos adversos
Feminino
Seguimentos
Seres Humanos
Isotretinoína/uso terapêutico
Masculino
Preparações de Plantas/efeitos adversos
Estudos Retrospectivos
Transaminases/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Dermatologic Agents); 0 (Dietary Proteins); 0 (Plant Preparations); EC 2.6.1.- (Transaminases); EH28UP18IF (Isotretinoin); MU72812GK0 (Creatine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170903
[St] Status:MEDLINE


  5 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28658462
[Au] Autor:Spring LK; Krakowski AC; Alam M; Bhatia A; Brauer J; Cohen J; Del Rosso JQ; Diaz L; Dover J; Eichenfield LF; Gurtner GC; Hanke CW; Jahnke MN; Kelly KM; Khetarpal S; Kinney MA; Levy ML; Leyden J; Longaker MT; Munavalli GS; Ozog DM; Prather H; Shumaker PR; Tanzi E; Torres A; Velez MW; Waldman AB; Yan AC; Zaenglein AL
[Ad] Endereço:Dermatology Department, Naval Hospital Camp Lejeune, Camp Lejeune, North Carolina.
[Ti] Título:Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations.
[So] Source:JAMA Dermatol;153(8):802-809, 2017 Aug 01.
[Is] ISSN:2168-6084
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: The notion that systemic isotretinoin taken within 6 to 12 months of cutaneous surgery contributes to abnormal scarring or delayed wound healing is widely taught and practiced; however, it is based on 3 small case series from the mid-1980s. Objective: To evaluate the body of literature to provide evidence-based recommendations regarding the safety of procedural interventions performed either concurrently with, or immediately following the cessation of systemic isotretinoin therapy. Evidence Review: A panel of national experts in pediatric dermatology, procedural/cosmetic dermatology, plastic surgery, scars, wound healing, acne, and isotretinoin was convened. A systematic PubMed review of English-language articles published from 1982 to 2017 was performed using the following search terms: isotretinoin, 13-cis-retinoic acid, Accutane, retinoids, acitretin, surgery, surgical, laser, ablative laser, nonablative laser, laser hair removal, chemical peel, dermabrasion, wound healing, safety, scarring, hypertrophic scar, and keloid. Evidence was graded, and expert consensus was obtained. Findings: Thirty-two relevant publications reported 1485 procedures. There was insufficient evidence to support delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures for patients currently receiving or having recently completed isotretinoin therapy. Based on the available literature, mechanical dermabrasion and fully ablative laser are not recommended in the setting of systemic isotretinoin treatment. Conclusions and Relevance: Physicians and patients may have an evidence-based discussion regarding the known risk of cutaneous surgical procedures in the setting of systemic isotretinoin therapy. For some patients and some conditions, an informed decision may lead to earlier and potentially more effective interventions.
[Mh] Termos MeSH primário: Cicatriz/etiologia
Fármacos Dermatológicos/efeitos adversos
Isotretinoína/efeitos adversos
Cicatrização/efeitos dos fármacos
[Mh] Termos MeSH secundário: Cicatriz/patologia
Fármacos Dermatológicos/administração & dosagem
Procedimentos Cirúrgicos Dermatológicos/métodos
Seres Humanos
Isotretinoína/administração & dosagem
Pele/efeitos dos fármacos
Pele/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents); EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1001/jamadermatol.2017.2077


  6 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28657366
[Au] Autor:Le Moigne M; Bulteau S; Grall-Bronnec M; Gerardin M; Fournier JP; Jonville-Bera AP; Jolliet P; Dreno B; Victorri-Vigneau C
[Ad] Endereço:a Dermato-Oncology Unit , University Hospital Hôtel-Dieu , Nantes , France.
[Ti] Título:Psychiatric disorders, acne and systemic retinoids: comparison of risks.
[So] Source:Expert Opin Drug Saf;16(9):989-995, 2017 Sep.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The link between isotretinoin, treatment of a severe form of acne, and psychiatric disorders remains controversial, as acne itself could explain the occurrence of psychiatric disorders. This study aims at assessing the disproportionality of psychiatric adverse events reported with isotretinoin in the French National PharmacoVigilance Database, compared with other systemic acne treatments and systemic retinoids. MATERIALS AND METHODS: Data were extracted from the French National PharmacoVigilance Database for systemic acne treatments, systemic retinoids and drugs used as comparators. Each report was subjected to double-blind analysis by two psychiatric experts. A disproportionality analysis was performed, calculating the number of psychiatric ADRs divided by the total number of notifications for each drug of interest. RESULTS: Concerning acne systemic treatments: all 71 reports of severe psychiatric disorders involved isotretinoin, the highest proportion of mild/moderate psychiatric adverse events was reported with isotretinoin (14.1%). Among systemic retinoids, the highest proportion of severe and mild/moderate psychiatric events occurred with isotretinoin and alitretinoin. CONCLUSION: Our study raises the hypothesis that psychiatric disorders associated with isotretinoin are related to a class effect of retinoids, as a signal emerges for alitretinoin. Complementary studies are necessary to estimate the risk and further determine at-risk populations.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Fármacos Dermatológicos/uso terapêutico
Transtornos Mentais/induzido quimicamente
Retinoides/uso terapêutico
[Mh] Termos MeSH secundário: Sistemas de Notificação de Reações Adversas a Medicamentos
Bases de Dados Factuais
Fármacos Dermatológicos/efeitos adversos
Feminino
França
Seres Humanos
Isotretinoína/efeitos adversos
Isotretinoína/uso terapêutico
Masculino
Transtornos Mentais/epidemiologia
Farmacovigilância
Retinoides/efeitos adversos
Risco
Índice de Gravidade de Doença
Tretinoína/efeitos adversos
Tretinoína/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Retinoids); 1UA8E65KDZ (alitretinoin); 5688UTC01R (Tretinoin); EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2017.1344641


  7 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28619552
[Au] Autor:Tolkachjov SN; Sahoo A; Patel NG; Lohse CM; Murray JA; Tollefson MM
[Ad] Endereço:Surgical Dermatology Group, Birmingham, Alabama. Electronic address: stan.tolkachjov@gmail.com.
[Ti] Título:Surgical outcomes of patients on isotretinoin in the perioperative period: A single-center, retrospective analysis.
[So] Source:J Am Acad Dermatol;77(1):159-161, 2017 07.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Fármacos Dermatológicos/efeitos adversos
Procedimentos Cirúrgicos Dermatológicos/efeitos adversos
Isotretinoína/efeitos adversos
Complicações Pós-Operatórias/etiologia
[Mh] Termos MeSH secundário: Cicatriz/etiologia
Seres Humanos
Período Perioperatório
Hemorragia Pós-Operatória/etiologia
Estudos Retrospectivos
Deiscência da Ferida Operatória/etiologia
Infecção da Ferida Cirúrgica/etiologia
Fatores de Tempo
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Dermatologic Agents); EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170617
[St] Status:MEDLINE


  8 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28538877
[Au] Autor:Kartal D; Yasar M; Kartal L; Özcan I; Borlu M
[Ad] Endereço:Department of Dermatology and Venereology - Erciyes University Faculty of Medicine - Kayseri, Turkey.
[Ti] Título:Effects of isotretinoin on the olfactory function in patients with acne.
[So] Source:An Bras Dermatol;92(2):191-195, 2017 Mar-Apr.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Background:: Isotretinoin is a synthetic analog of vitamin A. Recent studies support a role for retinoic acid in the recovery of olfactory function following injury in mice. Objective:: This study aimed at determining the effect of isotretinoin on olfactory function in patients who have acne and are otherwise healthy. Methods:: Forty-five patients (aged 25-40 years) with acne were included in the study. All patients underwent a rhinological examination. Olfactory function was assessed by the Sniffin' Sticks Test. The test was assessed at baseline and in the third month of isotretinoin treatment. Results:: Isotretinoin improved the performance of patients in the olfactory test. The SST score increased from 8.7±1.09 to 9.5±1.19 (p<0.001), prevalence of hyposmia decreased from 40% to 24% and normosmia increased from 60% to 75% (p=0.059). The percentage of patients whose olfactory function was categorized as "good" increased from 6% to 21.3%. This increase was statistically significant (p<0.05). Study limitations:: Absence of a control group is one of the limitations of this study. Also, we did not evaluate patients with smell test after stopping isotretinoin treatment. Conclusion:: We examined the effect of systemic isotretinoin on olfactory function. It can be concluded from the present investigation that isotretinoin therapy improves the sense of smell.
[Mh] Termos MeSH primário: Acne Vulgar/tratamento farmacológico
Isotretinoína/uso terapêutico
Olfato/efeitos dos fármacos
Tretinoína/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Seres Humanos
Isotretinoína/farmacologia
Masculino
Estudos Prospectivos
Tretinoína/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
5688UTC01R (Tretinoin); EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE


  9 / 3282 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28498204
[Au] Autor:Waldman A; Bolotin D; Arndt KA; Dover JS; Geronemus RG; Chapas A; Iyengar S; Kilmer SL; Krakowski AC; Lawrence N; Prather HB; Rohrer TE; Schlosser BJ; Kim JYS; Shumaker PR; Spring LK; Alam M
[Ad] Endereço:*Department of Dermatology, Northwestern University, Chicago, Illinois; †Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; ‡Section of Dermatology, University of Chicago Medicine, Chicago, Illinois; §SkinCare Physicians, Chestnut Hill, Massachusetts; ‖Laser & Skin Surgery Center of New York, New York, New York; ¶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; #Union Square Laser Dermatology, New York, New York; **Laser and Skin Surgery Center of Northern California, Sacramento, California; ††Department of Dermatology, University of California Davis School of Medicine, Davis, California; ‡‡Department of Dermatology, University of California San Diego Health System, San Diego, California; §§DermOne, LLC, West Conshohocken, Pennsylvania; ‖‖Division of Dermatology, Section of Procedural Dermatology, Cooper University Health Care, Marlton, New Jersey; ¶¶Westlake Dermatology and Cosmetic Surgery, Austin, Texas; ##Division of Plastic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; ***Department of Dermatology, Naval Medical Center, San Diego, California; †††Department of Dermatology, Naval Hospital Camp Lejeune, Camp Lejeune, North Carolina; Departments of ‡‡‡Otolaryngology, and §§§Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
[Ti] Título:ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use.
[So] Source:Dermatol Surg;43(10):1249-1262, 2017 Oct.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Currently, the isotretinoin (13-cis-retinoic acid) package insert contains language advising the discontinuation of isotretinoin for 6 months before performing cosmetic procedures, including waxing, dermabrasion, chemical peels, laser procedures, or incisional and excisional cold-steel surgery. It is common practice to follow this standard because of concerns regarding reports of sporadic adverse events and increased risk of scarring. OBJECTIVE: To develop expert consensus regarding the safety of skin procedures, including resurfacing, energy device treatments, and incisional and excisional procedures, in the setting of concurrent or recent isotretinoin use. MATERIALS AND METHODS: The American Society for Dermatologic Surgery authorized a task force of content experts to review the evidence and provide guidance. First, data were extracted from the literature. This was followed by a clinical question review, a consensus Delphi process, and validation of the results by peer review. RESULTS: The task force concluded that there is insufficient evidence to justify delaying treatment with superficial chemical peels and nonablative lasers, including hair removal lasers and lights, vascular lasers, and nonablative fractional devices for patients currently or recently exposed to isotretinoin. Superficial and focal dermabrasion may also be safe when performed by a well-trained clinician.
[Mh] Termos MeSH primário: Abrasão Química
Dermabrasão
Fármacos Dermatológicos/uso terapêutico
Procedimentos Cirúrgicos Dermatológicos
Isotretinoína/uso terapêutico
Terapia a Laser
Segurança do Paciente/normas
[Mh] Termos MeSH secundário: Abrasão Química/efeitos adversos
Cicatriz/etiologia
Cicatriz/prevenção & controle
Dermabrasão/efeitos adversos
Procedimentos Cirúrgicos Dermatológicos/efeitos adversos
Seres Humanos
Terapia a Laser/efeitos adversos
Dermatopatias/etiologia
Dermatopatias/prevenção & controle
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Dermatologic Agents); EH28UP18IF (Isotretinoin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001166


  10 / 3282 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28472572
[Au] Autor:Maor D; Chong AH
[Ti] Título:Rosacea.
[So] Source:Aust Fam Physician;46(5):277-281, 2017.
[Is] ISSN:0300-8495
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Rosacea is a chronic and common cutaneous condition characterised by symptoms of facial flushing and a broad spectrum of clinical signs. The clinical presentation for rosacea is varied, and there are four primary subtypes, which may overlap - erythrotelangiectatic, inflammatory, phymatous and ocular. It is important to recognise the different subtypes because of the differences in therapy. OBJECTIVE: The objective of this article is to provide evidence-based clinical updates to clinicians, specifically general practitioners (GPs), to assist with their everyday practice, and effective assessment and treatment of rosacea. DISCUSSION: Therapeutic modalities are chosen on the basis of the subtypes and clinical features identified; often a combination of these therapies is required.
[Mh] Termos MeSH primário: Rosácea/diagnóstico
Rosácea/fisiopatologia
Rosácea/terapia
[Mh] Termos MeSH secundário: Antibacterianos/farmacologia
Antibacterianos/uso terapêutico
Tartarato de Brimonidina/farmacologia
Tartarato de Brimonidina/uso terapêutico
Diagnóstico Diferencial
Doxiciclina/farmacologia
Doxiciclina/uso terapêutico
Seres Humanos
Isotretinoína/farmacologia
Isotretinoína/uso terapêutico
Ivermectina/farmacologia
Ivermectina/uso terapêutico
Terapia a Laser/métodos
Metronidazol/farmacologia
Metronidazol/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 140QMO216E (Metronidazole); 4S9CL2DY2H (Brimonidine Tartrate); 70288-86-7 (Ivermectin); EH28UP18IF (Isotretinoin); N12000U13O (Doxycycline)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE



página 1 de 329 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde